The Food and Drug Administration on Monday approved Biogen’s new Alzheimer’s drug, a decision with far-reaching implications for patients, clinicians, and others. Here’s a rundown on some basic questions and answers about the drug, known as Aduhelm.
Who can get the drug?
The drug, tested in patients with mild cognitive impairment, is approved for patients with Alzheimer’s. They will need an MRI within one year of starting treatment and will also have to undergo more MRIs during treatment.
How much does it cost?
Biogen said the yearly cost for a maintenance dose of Aduhelm, based on an average patient’s weight, would be $56,000. That’s a list price, not the net price or the price paid by patients with insurance. How much patients will pay out of pocket for the drug will depend on their insurance coverage.
About the Author Reprints
How can I join trial please. l live in South Africa and desperately would like to get medication .
Another promising drug in the pipeline:
https://www.alzforum.org/therapeutics/simufilam
Clinical trial sites:
https://www.cassavasciences.com/static-files/c45b6f43-ccc1-4391-bfed-e1c68fbae5fd
How can I join trial please
I have cognitive impairment diagnosed by geriatric Dr Fernando – Shellharbour Hospital. NSW. Australia